FibroBiologics

FBLGPhase 2

FibroBiologics is developing a novel class of biologic treatments based on fibroblasts, one of the most abundant cells in the human body. The company claims its fibroblast platform offers superior potency, easier sourcing, and lower manufacturing costs compared to stem cell therapies. With over 270 patents and an IND-cleared program for degenerative disc disease, FibroBiologics is positioning itself as a leader in next-generation regenerative medicine.

Market Cap

$17.3M

Focus

Cell & Gene Therapy

FBLG · Stock Price

USD 0.2528.85 (-99.13%)

Historical price data

AI Company Overview

Technology Platform

A proprietary platform utilizing fibroblast cells as a more potent, manufacturable, and cost-effective alternative to stem cells for regenerative medicine and immune modulation.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage	Watch
SoC + Low dose CYWC628 + SoC + High dose CYWC628	Diabetic Foot Ulcer (DFU)	Phase 1/2
Tolerogenic Fibroblasts	Multiple Sclerosis, Relapsing-Remitting	Phase 1

Opportunities

The primary opportunity is to disrupt the cell therapy market by proving fibroblasts are a superior therapeutic cell source to stem cells, enabling more effective and affordable treatments for large chronic disease markets like DDD, MS, and chronic wounds.

Success could also open new fields in immuno-aging and organ regeneration.

Risk Factors

Key risks include the unproven clinical superiority of fibroblasts versus established cell therapies, the high cash burn of a clinical-stage biotech with a broad pipeline, and the significant scientific and regulatory hurdles inherent in developing novel biologic therapies.

Competitive Landscape

FibroBiologics competes directly with mesenchymal stem cell (MSC) therapy developers (e.g., Mesoblast, DiscGenics) and broader regenerative medicine companies. Its differentiation is based on claimed fibroblast advantages in potency, sourcing, and cost, but this remains to be validated in large-scale clinical trials against these established competitors.